NCT01146808View on ClinicalTrials.gov

Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2012

Conditions
Hepatitis BLiver Transplantation
Interventions
DRUG

Adefovir dipivoxil and hepatitis B vaccination

Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose

Trial Locations (1)

10032

Center for Liver Disease and Transplantation at Columbia University Medical Center, New York

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Columbia University

OTHER